TFF Pharmaceuticals FY2023 net loss $21.2M, cash $5.5M; TFF TAC positive data

TFF Pharmaceuticals, Inc.

Cash $5.5M at Dec 31, 2023; raised $1.2M gross in March 2024 offering plus warrants at $8.00.
FY2023 net loss $21.2M (down from $31.8M in 2022); R&D $12.1M (-35%), G&A $10.6M (-23%).
Phase 2 TFF TAC: 8/8 patients transitioned from oral Tacrolimus, no acute rejection, 4/4 continued to long-term extension.
TFF VORI: 5/6 completed patients achieved clinical and mycologic response; no IPA-related mortality.
Company prioritizing TFF TAC, exploring strategic alternatives for TFF VORI; new board members appointed in Q4 2023.

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.9

TFF Pharmaceuticals, Inc. reported the fiscal year ended December 31, 2023 results: net income Net loss was $21.2 million.

Period: the fiscal year ended December 31, 2023
Net income: Net loss was $21.2 million
Result: reported results

Exact text from the filing

Net loss was $21.2 million for the year ended December 31, 2023

View on SEC.gov

326 earnings releases filed in the last 30 days. Browse all earnings releases →

Source: SEC EDGAR

accession 0001213900-24-027199

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.